COVID-19 vaccine generates immune structures critical for lasting immunity

-

 

COVID-19 vaccine generates immune structures critical for lasting immunity





Vaccines likely induce strong, persistent immunity to COVID-19.


The first two COVID-19 vaccines authorized for emergency use by the Food and Drug Administration (FDA) employed a technology that had never been used in FDA-approved vaccines. Both vaccines performed well in clinical trials, and both have been widely credited with reducing disease. Still, concerns remain over how long immunity induced by the new vaccine technology will last.

Now, a study from researchers at Washington University School of Medicine in St. Louis, published June 28 in the journal Nature, has found evidence that the immune response to such vaccines is both strong and potentially long-lasting. For example, nearly four months after the first dose, people who received the Pfizer vaccine still had so-called germinal centers in their lymph nodes churning out immune cells directed against SARS-CoV-2, the virus that causes COVID-19. Germinal centers, which form natural infection or vaccination, are boot camps for immune cells, a place where inexperienced cells are trained to better recognize the enemy and weapons are sharpened. So a better germinal center response may equal a better vaccine.

Moreover, vaccination led to high levels of neutralizing antibodies effective against three variants of the virus, including the Beta variant from South Africa that has shown some resistance to vaccines. Vaccination induced stronger antibody responses in people who had recovered from SARS-CoV-2 infection than those who had never been infected.

In April, both Pfizer and Moderna reported that their vaccines provided at least six months of protection. However, their reports were based on tracking whether vaccinated people came down with COVID-19. Other groups have monitored antibody levels in the blood and concluded that the vaccine provides at least months of protection. But nobody had looked to see how the immune response was developing in the body, which could provide important clues to the strength and persistence of the immune response without requiring years of follow-up.

"Germinal centers are the key to a persistent, protective immune response," said senior author Ali Ellebedy, Ph.D., an associate professor of pathology & immunology, of medicine, and of molecular microbiology. "Germinal centers are where our immune memories are formed. And the longer we have a germinal center, the stronger and more durable our immunity will be because there's a fierce selection process happening there, and only the best immune cells survive. We found that germinal centers were still going strong 15 weeks after the vaccine's first dose. We're still monitoring the germinal centers, and they're not declining; in some people, they're still ongoing. This is truly remarkable."

Scientists don't fully understand why some vaccines, such as the one for smallpox, induce strong protection that lasts a lifetime, while others, such as the vaccine for whooping cough, require regular boosters. But many suspect that the difference lies in the quality of the germinal centers induced by different vaccines.

The Pfizer and Moderna vaccines were created with mRNA technology. Unlike most vaccines, which provide bits of viral or bacterial proteins to trigger an immune response, mRNA-based vaccines provide instructions for the body to build and release foreign proteins, such as the spike protein in the case of the SARS-CoV-2 virus. To assess whether this new kind of vaccine induces a good germinal center response, Ellebedy and co-first author Jackson Turner, Ph.D., an instructor in pathology & immunology, teamed up with co-senior author Rachel Presti, MD, Ph.D., an associate professor of medicine, and co-first author Jane O'Halloran, MD, Ph.D., an assistant professor of medicine, and started the study once the first COVID-19 vaccine became available in mid-December 2020.

The team enlisted the help of co-authors Sharlene Teefey, MD, and William Middleton, MD, both professors of radiology, to perform ultrasound-guided sampling of the minuscule germinal centers in lymph nodes in the armpit. Teefey and Middleton extracted cells from 14 people who received the Pfizer vaccine. Samples were obtained three weeks after the first dose (just before administering the second dose) and at weeks four, five, and seven. Ten of the participants gave additional samples 15 weeks after the first dose. None of the participants previously had been infected with the virus that causes COVID-19.

Three weeks after the first dose, all 14 participants had formed germinal centers with B cells producing antibodies that target a key SARS-CoV-2 protein. The response expanded greatly after the booster shot and then stayed high. Even 15 weeks after the first dose, eight of 10 people still had detectable germinal centers containing B cells targeting the virus.

"This is evidence of a really robust immune response," Presti said. "Your immune system uses germinal centers to perfect the antibodies so they can bind well and last as long as possible. The antibodies in the blood are the end result of the process, but the germinal center is where it is happening."

The researchers also obtained blood samples from 41 people who received the Pfizer vaccine, including eight who previously had been infected with the virus that causes COVID-19. Samples were obtained before administering each dose of the vaccine and at weeks four, five, seven, and 15 after the first dose. In people without prior exposure to the virus, antibody levels rose slowly after the first dose and peaked one week after the second. People who previously had been infected already had antibodies in their blood before the first dose. Their levels shot up quickly after the first dose and peaked higher than the uninfected participants' levels.

"We didn't set out to compare the effectiveness of vaccination in people with and without a history of infection, but when we looked at the data we could see an effect," O'Halloran said. "If you've already been infected and then you get vaccinated, you get a boost to your antibody levels. The vaccine clearly adds benefit, even in the context of prior infection, which is why we recommend that people who have had COVID-19 get the vaccine."

This study was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), grant and contract numbers U01AI141990, 1U01AI150747, R01 AI157155, AI134907, 5T32CA009547, HHSN272201400006C, HHSN272201400008C, and 75N93019C00051; the NIH, grant number UL1TR001439; the Sealy & Smith Foundation; the Kleberg Foundation; the John S. Dunn Foundation; the Amon G. Carter Foundation; the Gilson Longenbaugh Foundation; the Summerfield Robert Foundation; and a Helen Hay Whitney Foundation, postdoctoral fellowship. In addition, this study utilized samples obtained from the Washington University School of Medicine's COVID-19 biorepository supported by the NIH/National Center for Advancing Translational Sciences, grant number UL1 TR002345.


Comments

Post a Comment

Popular posts from this blog

PEOPLE WITH OBESITY BURN LESS CALORIES DURING THE DAY

-
Image
  PEOPLE WITH OBESITY BURN LESS CALORIES DURING THE DAY Building on prior studies with healthy-weight participants, the new research includes different body sizes.         New research indicates that weight influences how and when bodies burn energy. An Oregon Health & Science University study published in the journal  Obesity  found people who have a healthy weight use more energy during the day, when most people are active and eat, while those who are obese spend more energy during the night when most people sleep. The study also found that during the day, those with obesity have higher levels of the hormone insulin -- a sign that the body is working harder to use glucose, an energy-packed sugar. "It was surprising to learn how dramatically the timing of when our bodies burn energy differed in those with obesity," said the study's first author, Andrew McHill, Ph.D., an assistant professor at the OHSU School of Nursing and the Oregon Institute of ...
Read more

WHAT CAUSES ITCHING, AND WHAT STOPS IT?

-
Image
  WHAT CAUSES ITCHING, AND WHAT STOPS IT?         It can be a relief to scratch the occasional itch, but when itch gets out of control, it can become a severe health problem. How does the body know when to stop? Scientists at UC San Francisco are getting close to an answer. In a breakthrough that could transform how doctors treat conditions from eczema to allergies, they have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation. The findings, published on October 13th in  Science Immunology , lay the groundwork for a new generation of drugs that interact more intelligently with the body's innate self-regulating ability. Previous approaches suggested that IL-31 signals itch and promotes skin inflammation. However, the UCSF team discovered that nerve cells, or neurons, that respond to IL-31, triggering a scratch, also prevent immune cells from overreacting and causing more ...
Read more

A VEGAN DIET IMPROVES CARDIOVASCULAR HEALTH, ACCORDING TO A NEW STUDY

-
Image
  A VEGAN DIET IMPROVES CARDIOVASCULAR HEALTH, ACCORDING TO A NEW STUDY         In a study with 22 pairs of identical twins, Stanford Medicine researchers and their colleagues have found that a vegan diet improves cardiovascular health in as little as eight weeks. Although it's well-known that eating less meat improves cardiovascular health, diet studies often need to be enhanced by genetic differences, upbringing, and lifestyle choices. By studying identical twins, however, the researchers were able to control for genetics and limit the other factors, as the twins grew up in the same households and reported similar lifestyles. "Not only did this study provide a groundbreaking way to assert that a vegan diet is healthier than the conventional omnivore diet, but the twins were also a riot to work with," said Christopher Gardner, Ph.D., the Rehnborg Farquhar Professor and a professor of medicine. "They dressed the same, they talked the same, and they had a banter ...
Read more